<DOC>
	<DOCNO>NCT01650441</DOCNO>
	<brief_summary>The objective study evaluate effect combination formoterol beclometasone dipropionate dry powder inhaler ( NEXThaler® ) central peripheral airway dimension asthmatic patient . Therefore Computational Fluid Dynamics ( CFD ) use . Further , effect combination therapy lung function ( spirometry , resistance diffusion ) , Asthma Control Test ( ACT™ ) Asthma Control Questionnaire ( ACQ ) assess safety evaluate .</brief_summary>
	<brief_title>Study Assess Effect NEXThaler® Device ( DPI - Dry Powder Inhaler ) Central Peripheral Airway Dimensions Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Patients moderate asthma define current GINA guideline . Patients belong 2 category : Group 1 ( n=15 20 , least 4 current smoker ) : Patients well control ( partially control uncontrolled accord GINA guideline ) use medium daily dose ICS medium dose ICS + long act inhale 2agonists ( LABA ) ( definition please refer addendum section 15 ) give least 6 week largeparticle formulation ( non extrafine ) . Group 2 ( n=15 20 , least 4 current smoker ) : Patients well control ( accord GINA guideline ) use medium daily dose ICS + LABA ( definition please refer addendum section 15 ) give least 6 week largeparticle formulation ( non extrafine ) . 2 . Male female patient age ≥18 year 3 . Patients document diagnosis asthma accord GINA guideline 4 . Patients cooperative attitude ability train correctly use Foster NEXThaler DPI 5 . Written inform consent obtain 1 . Patients treat extrafine ICS either alone LABA 2 . Pregnant lactating female female risk pregnancy screen willing use appropriate contraception method study period 3 . Inability carry pulmonary function test 4 . History near fatal asthma 5 . Hospitalization due asthma symptomatic infection airways previous 8 week 6 . Patients uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study 7 . Cancer 8 . Current alcohol drug abuse 9 . Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient 10 . Patients unlikely comply protocol unable understand nature , scope possible consequence study 11 . Patients receive investigational new drug within last 4 week prior screen visit 12 . Patients treat nonpermitted concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>NEXThaler®</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Beclomethasone Dipropionate</keyword>
	<keyword>Computational Fluid Dynamics</keyword>
	<keyword>Functional Imaging</keyword>
	<keyword>Central Peripheral Airways</keyword>
	<keyword>Asthma Control Test ( ACT™ )</keyword>
	<keyword>Asthma Control Questionnaire ( ACQ )</keyword>
</DOC>